Candel Therapeutics/$CADL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Candel Therapeutics
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Ticker
$CADL
Sector
Primary listing
Employees
38
Headquarters
Website
CADL Metrics
BasicAdvanced
$318M
-
-$0.52
-0.88
-
Price and volume
Market cap
$318M
Beta
-0.88
52-week high
$9.13
52-week low
$4.25
Average daily volume
789K
Financial strength
Current ratio
7.041
Quick ratio
6.842
Long term debt to equity
1.156
Total debt to equity
9.246
Interest coverage (TTM)
-24.93%
Profitability
EBITDA (TTM)
-34.405
Management effectiveness
Return on assets (TTM)
-33.39%
Return on equity (TTM)
-55.18%
Valuation
Price to book
3.52
Price to tangible book (TTM)
3.52
Price to free cash flow (TTM)
-8.202
Free cash flow yield (TTM)
-12.19%
Free cash flow per share (TTM)
-0.706
Growth
Earnings per share change (TTM)
-69.46%
3-year earnings per share growth (CAGR)
-9.94%
CADL News
AllArticlesVideos
Candel Therapeutics secures RMAT for prostate cancer – ICYMI
Proactive Investors·7 days ago
Candel Therapeutics advances toward prostate cancer therapy filing after trial success
Proactive Investors·1 week ago
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409
Proactive Investors·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Candel Therapeutics stock?
Candel Therapeutics (CADL) has a market cap of $318M as of August 23, 2025.
What is the P/E ratio for Candel Therapeutics stock?
The price to earnings (P/E) ratio for Candel Therapeutics (CADL) stock is 0 as of August 23, 2025.
Does Candel Therapeutics stock pay dividends?
No, Candel Therapeutics (CADL) stock does not pay dividends to its shareholders as of August 23, 2025.
When is the next Candel Therapeutics dividend payment date?
Candel Therapeutics (CADL) stock does not pay dividends to its shareholders.
What is the beta indicator for Candel Therapeutics?
Candel Therapeutics (CADL) has a beta rating of -0.88. This means that it has an inverse relation to market volatility.